Walleye Capital’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$149K Sell
4,573
-81,798
-95% -$2.63M ﹤0.01% 3499
2025
Q4
$3.04M Buy
86,371
+30,113
+54% +$1.07M 0.01% 1520
2025
Q3
$1.48M Buy
56,258
+54,625
+3,345% +$1.63M 0.01% 1796
2025
Q2
$43.3K Sell
1,633
-33,866
-95% -$892K ﹤0.01% 4081
2025
Q1
$857K Buy
35,499
+34,799
+4,971% +$1.1M ﹤0.01% 2102
2024
Q4
$28.2K Sell
700
-7,139
-91% -$407K ﹤0.01% 4455
2024
Q3
$496K Buy
7,839
+1,655
+27% +$97.1K ﹤0.01% 3307
2024
Q2
$328K Sell
6,184
-10,016
-62% -$657K ﹤0.01% 3902
2024
Q1
$1.33M Buy
+16,200
New +$721K ﹤0.01% 2314
2023
Q3
Sell
-81,251
Closed -$1.32M 5357
2023
Q2
$1.32M Buy
81,251
+38,187
+89% +$800K ﹤0.01% 1625
2023
Q1
$717K Sell
43,064
-170,247
-80% -$1.76M 0.01% 1400
2022
Q4
$2.01M Sell
213,311
-885,019
-81% -$3.95M 0.04% 578
2022
Q3
$2.99M Buy
1,098,330
+802,330
+271% +$2.63M 0.06% 368
2022
Q2
$855K Buy
296,000
+218,982
+284% +$542K 0.02% 728
2022
Q1
$231K Buy
+77,018
New +$276K 0.01% 1441
2020
Q1
Sell
-22,736
Closed -$182K 1716
2019
Q4
$182K Buy
+22,736
New +$166K 0.01% 1149
2018
Q3
$306K Buy
+17,574
New +$209K 0.14% 175

Other funds holding VKTX

Walleye Capital's VKTX Position: Q1 2026 in Review

Walleye Capital reduced its Viking Therapeutics (VKTX) stake by 95% in Q1 2026, selling an estimated $2.63M and leaving 4,573 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #3499.

Walleye Capital first reported a position in VKTX in Q3 2018 and has held it in 17 quarters since. The position peaked at $3.04M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Walleye Capital held 4,573 shares of Viking Therapeutics worth $149K as of Q1 2026.
  • Walleye Capital sold 81,798 Viking Therapeutics shares in Q1 2026, an estimated $2.63M.
  • Viking Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3499 holding.
  • Walleye Capital first reported a position in Viking Therapeutics in Q3 2018 and has held it in 17 quarters since.
  • Walleye Capital's Viking Therapeutics position peaked at $3.04M in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.